Variable | Subgroups | Entire cohort | Validation cohort for the Katagiri’s scoring system | ||
---|---|---|---|---|---|
Median survival (m) | P value | Median survival (m) | P value | ||
Gender | Men | 8.0 | 3.0 | ||
Women | 4.0 | < 0.001 | 9.0 | < 0.001 | |
Age | ≤ 64 | 5.0 | 4.0 | ||
≥ 65 | 4.0 | 0.604 | 3.0 | 0.529 | |
KPS | 10–60 | 3.0 | 3.0 | ||
70–80 | 5.0 | 4.0 | |||
90–100 | 8.0 | < 0.001 | 8.0 | 0.007 | |
ECOG PS | 0–2 | 6.0 | 5.0 | ||
3–4 | 3.0 | < 0.001 | 3.0 | 0.003 | |
Primary lesion | Lung cancer | 4.0 | 3.0 | ||
Breast cancer | 13.0 | 20.0 | |||
Prostate cancer | 8.0 | 8.0 | |||
Others | 4.0 | < 0.001 | 4.0 | < 0.001 | |
Primary characteristics | Slow | 10.0 | 13.0 | ||
Moderate | 8.0 | 8.0 | |||
Rapid | 3.0 | < 0.001 | 3.0 | < 0.001 | |
Visceral metastases | No | 11.0 | 11.0 | ||
Nodular | 4.0 | 4.0 | |||
Disseminated | 2.0 | < 0.001 | 2.0 | < 0.001 | |
Laboratory data | Normal | 12.0 | 11.0 | ||
Abnormal | 4.0 | 4.0 | |||
Critical | 2.0 | < 0.001 | 2.0 | < 0.001 | |
Previous chemotherapy | No | 6.0 | 5.0 | ||
Yes | 4.0 | < 0.001 | 3.0 | < 0.001 | |
Multiple bone metastases | No | 5.0 | 4.0 | ||
Yes | 4.0 | 0.691 | 4.0 | 0.961 | |
Katagiri score | 0–3 | 27.0 | |||
4–6 | 6.0 | ||||
7–10 | 2.0 | < 0.001 |